The Influence of Low-Temperature Plasma on Skin Scarring Processes: Pathomorphological Mechanisms and Possibilities for Tissue Remodeling.

Let us begin by examining the relevance of the problem of scar-related skin changes. Scar alterations of the skin represent a common and clinically significant outcome of inflammatory, traumatic, and surgical damage to the integument. Scar formation is the result of a complex, multistage wound-healing process that includes the phases of inflammation, proliferation, and tissue remodeling. Dysregulation of any of these stages leads to pathological scarring, manifested by the formation of atrophic, hypertrophic, or keloid scars.
From a clinical perspective, scars constitute not only a cosmetic defect but also a significant medical and social problem. Depending on their localization and morphological type, they may be associated with functional impairments (restricted mobility, contractures), chronic discomfort, pain, pruritus, and pronounced psycho-emotional disturbances. The presence of visible scars significantly reduces patients’ quality of life, negatively affecting social adaptation, self-esteem, and emotional well-being.
Despite the wide range of available therapeutic approaches, the correction of scar-related skin changes remains one of the most challenging tasks in modern dermatology and aesthetic medicine. Traditional treatment methods are often aimed at eliminating the external manifestations of the scar without addressing the underlying pathomorphological mechanisms of its formation. This results in limited therapeutic effectiveness, a high recurrence rate, and the risk of adverse effects, including hyperpigmentation, secondary fibrosis, and disruption of skin reparative processes.
Next, we will consider modern approaches to scar treatment and the need for new technologies.
Currently, pharmacological, device-based, and surgical methods are used to correct scar-related skin changes. Pharmacotherapy includes the use of corticosteroids, enzymatic agents, retinoids, and other medications aimed at suppressing inflammation and reducing fibrosis. However, these methods are often associated with skin atrophy, impaired microcirculation, and systemic side effects, especially with long-term use.
Device-based technologies, particularly laser therapy, as well as fractional and non-ablative techniques, have become widespread due to their ability to improve skin texture and stimulate dermal remodeling. Nevertheless, their effectiveness largely depends on the type of scar and individual patient characteristics and is limited by the risk of post-inflammatory hyperpigmentation, prolonged recovery periods, and the potential exacerbation of fibrotic changes if treatment parameters are improperly selected.
Surgical methods of scar correction, including excision and reconstructive plastic techniques, are used primarily in cases of pronounced tissue deformities. However, they involve additional skin trauma and do not exclude the possibility of recurrent scar formation, especially in patients predisposed to pathological scarring.
In this regard, recent years have seen growing interest in physical treatment modalities capable of exerting a multifactorial influence on skin healing processes. Particular attention has been drawn to low-temperature plasma, which possesses unique physicobiological properties and is capable of modulating inflammation, cellular activity, and extracellular matrix remodeling without causing pronounced thermal tissue damage.
The aim of this article is to analyze the pathomorphological mechanisms underlying the formation of skin scars and to substantiate the effectiveness of low-temperature plasma (Plasma Health) as a promising method for modulating healing and scar tissue remodeling processes. Particular emphasis is placed on the influence of plasma exposure on the inflammatory cascade, fibroblast activity, and restoration of the structural organization of the dermis.
Let us proceed to the topic of skin structure and the physiology of wound healing.
The skin is the largest organ of the human body and performs barrier, protective, immune, thermoregulatory, and sensory functions. From a morphological perspective, the skin is a complex multilayered structure consisting of the epidermis, dermis, and hypodermis, each of which plays a key role in regeneration and scarring processes.
The epidermis is composed of stratified squamous keratinized epithelium and is predominantly represented by keratinocytes, which provide barrier function and participate in the early stages of wound healing. In response to injury, keratinocytes actively migrate, proliferate, and secrete biologically active molecules, including growth factors and cytokines that regulate the inflammatory and reparative response. In addition, the epidermis contains immunocompetent cells, such as Langerhans cells, which participate in initiating innate and adaptive immune responses.
The dermis is dense connective tissue that provides the skin with mechanical strength and elasticity. The principal cellular elements of the dermis are fibroblasts, which synthesize components of the extracellular matrix (ECM), including collagen and elastin fibers, as well as proteoglycans and glycosaminoglycans. Fibroblasts play a central role in scar formation, as during pathological healing they acquire increased proliferative activity and transform into myofibroblasts responsible for excessive collagen synthesis and tissue contraction.
Endothelial cells forming the vascular network of the dermis play an important role in skin regeneration. They ensure angiogenesis, the delivery of oxygen and nutrients to the injury site, and participate in the regulation of inflammatory processes. Dermal immune cells—macrophages, neutrophils, mast cells, and lymphocytes—coordinate the inflammatory response and significantly influence the outcome of healing.
The extracellular matrix of the dermis is a dynamic structure composed predominantly of type I and type III collagen, elastin, and proteoglycans. Under normal wound-healing conditions, there is a temporary predominance of type III collagen, followed by its replacement with stronger and more organized type I collagen during the remodeling phase. Disruption of this balance leads to the formation of disorganized scar tissue with altered mechanical and functional properties.
The wound-healing process is a strictly regulated sequence of biological events that includes four interrelated phases: hemostasis, inflammation, proliferation, and remodeling. Each of these phases is critical for restoring skin integrity and structural organization.
The hemostasis phase begins immediately after skin injury and is aimed at stopping bleeding. During this period, platelet aggregation and fibrin clot formation occur. The clot not only performs a mechanical protective function but also serves as a matrix for the migration of cells involved in subsequent healing stages. In addition, platelets release growth factors (PDGF, TGF-β, etc.) that initiate the cascade of reparative processes.
The inflammatory phase is characterized by activation of the innate immune response. Neutrophils and macrophages migrate to the injury site, where they remove cellular debris and microorganisms and secrete pro-inflammatory cytokines and growth factors. Regulation of matrix metalloproteinase (MMP) activity—enzymes responsible for degrading damaged extracellular matrix components—plays a crucial role at this stage. Controlled MMP activity is necessary for wound cleansing and tissue preparation for subsequent regeneration. However, an imbalance between metalloproteinases and their tissue inhibitors (TIMP) may contribute to either excessive matrix degradation or, conversely, its accumulation, thereby creating conditions for fibrotic tissue formation.
Despite the importance of the inflammatory response in initiating regeneration, its excessive or prolonged activation is one of the key factors in the development of pathological scarring. The baseline functional state of cells within injured tissue plays a significant role in determining the intensity and duration of inflammation. Cells previously exposed to oxidative stress or chronic subclinical inflammation tend to hyperexpress pro-inflammatory cytokines and mediators upon repeated injury. This results in a more prolonged and often uncontrolled inflammatory response. Under such conditions, immune cells at the injury site exhibit increased reactivity and a tendency toward hyperresponsiveness, increasing the risk of transition from physiological inflammation to a chronic state and promoting the development of pathological fibrosis.
During the proliferation phase, active migration and proliferation of keratinocytes, fibroblasts, and endothelial cells occur. Granulation tissue is formed, angiogenesis is enhanced, and synthesis of extracellular matrix components, predominantly type III collagen, begins. At this stage, the foundation of the future structure of the repaired tissue is established, and the subsequent direction of remodeling is determined.
The remodeling phase is the longest and may last from several months to several years. During this period, extracellular matrix reorganization occurs, type III collagen is replaced by stronger and more organized type I collagen, excessive vascular networks are reduced, and activated fibroblasts and myofibroblasts undergo apoptosis. Disruption of remodeling processes, including persistent high myofibroblast activity, imbalance of the MMP/TIMP system, and predominance of collagen synthesis over degradation, leads to the formation of hypertrophic or keloid scars.
Thus, pathological skin scarring is the result of disruption of the finely balanced mechanisms of physiological wound healing. Targeting key cellular and molecular processes at each stage of regeneration represents a promising direction in the prevention and correction of scar-related skin changes.
Let us consider the different types of scars and their characteristics.
Skin scars are the result of a reparative process aimed at restoring the integrity of the integument following injury. Depending on healing characteristics, depth of damage, and individual biological responses, several main types of scars are distinguished, differing in clinical manifestations and morphological structure.
Normotrophic scars are formed during physiological wound healing and are characterized by an adequate balance between synthesis and degradation of extracellular matrix components. Such scars are located at the level of the surrounding skin, have an elastic consistency, and are generally not associated with functional impairment. Morphologically, they retain an organized arrangement of collagen fibers and moderate cellular activity.
Atrophic scars arise as a result of insufficient fibroblast proliferation and deficient synthesis of collagen and other dermal matrix components. Clinically, they present as depressed areas of the skin and are often observed after inflammatory dermatoses, particularly post-acne. Atrophic scars are characterized by dermal thinning, reduced collagen fiber density, and impaired microcirculation.
Hypertrophic scars develop due to excessive collagen production while remaining confined within the boundaries of the original injury. They protrude above the skin surface, have a dense consistency, and may be accompanied by subjective symptoms such as pruritus or tenderness. Unlike keloids, hypertrophic scars tend to undergo partial regression over time.
Keloid scars represent the most severe form of pathological scarring and are characterized by uncontrolled growth of scar tissue beyond the borders of the original wound. They are distinguished by aggressive clinical behavior, a high recurrence rate, and pronounced subjective complaints. Keloid scars are associated with profound dysregulation of cellular signaling and immune mechanisms involved in wound healing.
Let us examine the clinical and morphological features of different types of scars.
The key morphological difference between various types of scars lies in the structure and organization of collagen fibers. In normotrophic scars, type I collagen forms a relatively organized network that is structurally close to intact dermis. In atrophic scars, there is a pronounced deficiency of collagen, reduced density, and disruption of the spatial organization of fibers. In hypertrophic and keloid scars, excessive accumulation of collagen—predominantly types I and III—is observed, with dense and chaotic fiber arrangement, leading to decreased tissue elasticity.
The degree of vascularization also differs significantly depending on the type of scar. Atrophic scars are characterized by reduced vascular network density and impaired microcirculation, whereas hypertrophic and keloid scars, especially in the early stages of formation, demonstrate increased vascularization due to active angiogenesis. Over time, the vascular network in hypertrophic scars may partially regress, whereas in keloid scars angiogenic activity persists for a prolonged period.
Fibroblast and myofibroblast activity is one of the determining factors in scar pathogenesis. In atrophic scars, a reduction in both the number and functional activity of fibroblasts is observed, whereas in hypertrophic and particularly keloid scars, fibroblast hyperplasia and persistent presence of myofibroblasts are noted. These cells are characterized by increased production of collagen, growth factors, and inflammatory mediators, thereby contributing to the progression of fibrosis.
At the molecular level, different types of scars differ in the nature of cellular signaling. In pathological scarring, signaling pathways associated with TGF-β, CTGF, PDGF, and NF-κB are activated, leading to enhanced fibrogenesis and suppression of fibroblast apoptosis mechanisms. In contrast, atrophic scars are characterized by insufficient activation of regenerative signaling cascades and reduced expression of growth factors necessary for complete dermal restoration.
Thus, the clinical diversity of scar-related skin changes reflects profound differences in the cellular and molecular mechanisms of healing. Understanding these differences is fundamentally important for selecting an appropriate therapeutic strategy and substantiating the use of methods capable of modulating key components of pathological scarring.
Let us further explore the pathomorphology of scar formation.
Inflammation is a physiologically necessary stage of wound healing; however, its prolonged or excessive course is regarded as one of the key pathogenetic factors in pathological skin scarring. Under normal healing conditions, the inflammatory phase is limited in duration and concludes with the transition to proliferative and reparative processes. In chronic inflammation, sustained activation of immune and stromal cells develops, disrupting the regulation of tissue regeneration.
Chronic inflammation is accompanied by persistent tissue infiltration by neutrophils, macrophages, and lymphocytes, which secrete a broad spectrum of pro-inflammatory mediators, including TNF-α, IL-1β, IL-6, and chemokines. Prolonged presence of these factors stimulates fibroblast proliferation, enhances synthesis of extracellular matrix components, and suppresses mechanisms of their physiological degradation.
Particular importance in scar pathogenesis is attributed to the imbalance between pro-inflammatory and anti-inflammatory mediators. Insufficient activity of anti-inflammatory cytokines, such as IL-10, as well as dysfunction of regulatory immune cells, leads to persistence of an inflammatory microenvironment at the injury site. This creates conditions for the transition from acute to chronic inflammation, thereby promoting the formation of hypertrophic and keloid scars.
Fibroblasts are key effector cells of the dermis that determine the outcome of skin healing. Under normal conditions, their activation is temporary and strictly controlled by signaling molecules and growth factors released by macrophages during the inflammatory phase. However, in pathological scarring, excessive fibroblast proliferation and their differentiation into myofibroblasts—highly active cells with contractile capacity and increased collagen production—occur.
Myofibroblasts synthesize significant amounts of type I and III collagen, fibronectin, and other extracellular matrix components, leading to the formation of dense fibrotic tissue. Under normal healing conditions, these cells undergo apoptosis during the remodeling stage, ensuring gradual restoration of dermal structure.
In hypertrophic and especially keloid scars, disruption of myofibroblast apoptosis mechanisms is observed. These cells maintain high metabolic activity and continue synthesizing matrix proteins even after wound epithelialization is complete. One of the key regulators of this process is transforming growth factor β (TGF-β), the excessive expression of which promotes fibrogenesis and resistance of myofibroblasts to apoptotic signals.
Regarding disruption of extracellular matrix remodeling, this process represents the final stage of skin healing and is aimed at restoring its mechanical and functional properties. Under normal conditions, it is based on a balanced interaction between matrix metalloproteinases (MMPs), responsible for matrix component degradation, and their tissue inhibitors (TIMPs), which regulate proteolytic activity.
In pathological scarring, a pronounced imbalance of the MMP/TIMP system is observed, leading to reduced degradation of excessively synthesized collagen. As a result, dense, disorganized collagen fibers accumulate in the dermis, oriented chaotically and lacking normal architectural structure. This is accompanied by decreased tissue elasticity, impaired microcirculation, and the formation of clinically significant scar changes.
An additional factor of pathological remodeling is alteration in the ratio of type I to type III collagen. Predominance of coarse type I collagen combined with insufficient matrix degradation contributes to the formation of rigid fibrotic tissue characteristic of hypertrophic and keloid scars. Impaired dynamic turnover of the extracellular matrix renders such scars resistant to spontaneous regression and to conventional treatment methods.
Let us outline the factors influencing normal skin healing.
The process of skin healing is the result of a complex interaction between local and systemic factors that determine the nature of the inflammatory response, the activity of dermal cells, and the effectiveness of extracellular matrix remodeling. Disruption of any of these factors may shift physiological healing toward pathological scarring.
Genetic characteristics of the patient play a significant role in scar formation. It has been established that susceptibility to hypertrophic and keloid scars is associated with increased expression of genes regulating collagen synthesis, TGF-β activity, and fibroblast resistance to apoptosis. Genetically determined features of the immune response also influence the duration of the inflammatory phase, which may contribute to chronic inflammation and enhanced fibrogenesis.
Age-related changes in the skin substantially affect its regenerative potential. In elderly patients, decreased proliferative activity of keratinocytes and fibroblasts, impaired microcirculation, and slowed angiogenesis are observed, increasing the risk of atrophic scar formation. Conversely, in younger patients, particularly during periods of hormonal activity, elevated levels of growth factors and hormones may promote a hyperreactive fibroblast response and the development of hypertrophic scars.
Hormonal status, including levels of estrogens, androgens, and glucocorticoids, directly influences inflammatory processes, collagen synthesis, and dermal remodeling. Hormonal imbalance may alter the course of healing and contribute to the formation of pathological scar tissue.
Special attention should be given to infection and microbial contamination. Infectious contamination of a wound is one of the most significant factors disrupting normal skin healing. The presence of bacterial or fungal microflora sustains chronic inflammation, enhances the production of pro-inflammatory cytokines, and leads to tissue destruction. Microbial toxins and metabolic by-products of pathogens may impair cell migration, inhibit angiogenesis, and promote excessive fibrosis.
Even subclinical microbial contamination may substantially affect healing outcomes, increasing the risk of coarse scar formation and reducing the effectiveness of therapeutic interventions.
Tissue hypoxia also plays a critical role. Adequate blood supply and tissue oxygenation are essential conditions for normal skin healing. Hypoxia in the area of injury leads to disruption of cellular energy metabolism, decreased fibroblast activity, and slowed extracellular matrix synthesis. At the same time, chronic hypoxia may paradoxically stimulate pathological angiogenesis and fibrosis through activation of hypoxia-inducible factors (HIF).
Impaired microcirculation, characteristic of scar tissue, perpetuates a vicious cycle of hypoxia and fibrosis, rendering such scars resistant to spontaneous remodeling.
The presence of systemic diseases, such as diabetes mellitus, autoimmune disorders, connective tissue diseases, and vascular pathologies, significantly impairs skin regeneration processes. These conditions are accompanied by chronic inflammation, microcirculatory disturbances, and reduced cellular reparative activity, thereby increasing the risk of pathological scar formation and delaying their correction.
Pharmacological influences should also be considered in this context. Drug therapy has a significant impact on skin healing. Prolonged use of glucocorticosteroids, cytostatics, and immunosuppressive agents may suppress cellular proliferation and angiogenesis, contributing to the formation of atrophic scars. Conversely, irrational use of stimulatory agents may enhance fibrosis and lead to hypertrophic scarring.
Thus, skin healing represents the result of a finely balanced interaction among numerous factors. The multifactorial nature of scar pathogenesis substantiates the need for therapeutic approaches capable of simultaneously influencing inflammation, microbial load, cellular activity, and tissue remodeling processes.
Let us now turn to the principles underlying the Plasma Health gas ionization methodology.
The Plasma Health technology is based on the controlled ionization of atmospheric air with the formation of low-temperature plasma—a gaseous mixture containing ions, electrons, excited atoms and molecules, as well as reactive particles. As a result of an electrical discharge, neutral gas is transformed into an active ionized medium possessing pronounced biological effects.
The method is based on the generation of an electrical impulse that initiates excitation of an electric arc and subsequent ionization of air in the immediate vicinity of the treatment zone. The resulting plasma medium represents a mixture of positively and negatively charged ions, free electrons, reactive oxygen and nitrogen species, as well as molecules in an excited state. The temperature of heavy particles remains close to physiological levels, thereby excluding thermal tissue damage.
A distinctive feature of Plasma Health technology is the simultaneous and synergistic effect on tissues of two factors: the products of air ionization and the local electric field generated in the discharge zone. The gaseous mixture of active particles comes into contact with the surface of the skin or mucous membrane, initiating a cascade of biochemical reactions at the cellular level. At the same time, the electrical impulse alters the membrane potential of cells, increases cell membrane permeability, and activates intracellular signaling pathways.
The combined action of chemically active plasma components and electrical stimulation provides comprehensive modulation of cellular activity. Processes regulating inflammation, normalization of fibroblast function, activation of angiogenesis, and remodeling of the extracellular matrix are initiated in tissues. Unlike thermal methods, gas ionization technology does not cause coagulative necrosis and does not create a zone of secondary tissue damage, which is particularly important when working with scar tissue.
Thus, the Plasma Health method represents a physicochemical technology that ensures the controlled creation of a biologically active plasma environment directly within the therapeutic zone. The synergism of the electrical impulse and air ionization products forms the basis of its clinical effectiveness in the correction of scar-related skin changes.
Physical principles of low-temperature plasma (Plasma Health) and products of gas ionization.
Plasma represents a distinct, fourth state of matter characterized by partial or complete ionization of a gas. Unlike solid, liquid, and gaseous states, plasma contains a significant number of charged particles—electrons and ions—as well as neutral atoms and molecules in excited states. The presence of free charges determines its high reactivity and sensitivity to electric and magnetic fields.
The biological effect of low-temperature plasma is due to the combined action of several physical and chemical factors that arise during the ionisation of gas.
The biological effects of low-temperature plasma are due to the combined action of several physical and chemical factors that arise during the ionisation of gas.
The key active agents are reactive oxygen and nitrogen species (RONS), including superoxide anion, hydroxyl radicals, hydrogen peroxide, nitric oxide, and peroxynitrite. These molecules possess high biological activity and are capable of modulating cellular signaling, exerting antimicrobial effects, and influencing inflammation and regeneration processes. At physiological concentrations, RONS function as secondary messengers, regulating proliferation, migration, and differentiation of skin cells.
An important component of low-temperature plasma exposure is the local electric fields generated in the plasma discharge zone. Electric fields can alter cell membrane permeability, activate ion channels, and enhance intercellular communication. These effects increase cellular sensitivity to signaling molecules and enhance reparative processes within tissues.
An additional factor is the low-intensity ultraviolet radiation generated by plasma. Unlike conventional ultraviolet irradiation, its intensity during plasma exposure is significantly lower and does not cause DNA damage. Nevertheless, it contributes to the antimicrobial effect and may participate in the regulation of the local immune response of the skin.
Thus, low-temperature plasma represents a multifactorial physicochemical system capable of simultaneously influencing microbial contamination, inflammatory processes, and cellular mechanisms of regeneration. It is precisely this complexity of action that makes plasma technologies a promising tool for pathogenetically oriented correction of scar-related skin changes.
It is essential to emphasize the mechanisms of action of low-temperature plasma on scar tissue.
Low-temperature plasma exerts a multilevel effect on scar tissue, targeting the key pathogenetic mechanisms underlying its formation and persistence. Unlike traditional methods, plasma exposure is not limited to symptomatic correction but is aimed at modulating inflammation, cellular activity, and extracellular matrix remodeling.
In the context of correcting already formed fibrotic hyperplasia, the best corrective outcomes are achieved with the use of thermal plasma, as this technique allows rapid ablation of hypertrophied fibers. At the same time, this method demonstrates less heat propagation to surrounding tissues compared with the above-mentioned hardware or chemical methods (lasers, coagulators). This, in turn, results in a controlled level of inflammation and a reduction in the expression of proinflammatory cytokines, followed by an overall decrease in immune response activity.
In the context of preventing hypertrophic scarring after skin injury, the key prognostic factor is timely and pathogenetically substantiated therapeutic intervention directed at injured tissues, aimed at forming an adequate inflammatory response. Controlled inflammation is a necessary stage of regeneration; however, its excessive or prolonged activation significantly increases the risk of excessive fibrosis. Therefore, reducing the intensity and duration of the inflammatory reaction without suppressing physiological healing mechanisms represents a strategically important objective in the correction of scar changes.
One of the key effects of low-temperature plasma is its ability to reduce the severity of the inflammatory response in scar tissue. Under the influence of reactive oxygen and nitrogen species (RONS), modulation of signaling pathways responsible for the expression of proinflammatory cytokines occurs. Experimental and clinical data indicate decreased levels of TNF-α, IL-1β, and IL-6 in tissues following exposure to ionic metabolites.
A central role in this process is played by inhibition of the NF-κB signaling pathway—one of the principal regulators of inflammatory response and fibrogenesis. Suppression of NF-κB activation leads to reduced transcription of genes encoding proinflammatory mediators, promoting the transition of inflammation from a chronic to a resolving state. This creates favorable conditions for normalization of reparative processes and prevention of further fibrosis progression.
Thus, the gas ionization methodology contributes to restoring the balance between proinflammatory and anti-inflammatory mechanisms, which is fundamentally important in the correction of pathological scarring.
Let us focus on the effects on fibroblasts and myofibroblasts. Fibroblasts and myofibroblasts are the principal cellular effectors of scar tissue, and their pathological activation underlies excessive fibrogenesis. Low-temperature plasma exerts a modulatory effect on these cells, normalizing their proliferative activity and functional state.
Under the influence of plasma-derived RONS, regulation of the fibroblast cell cycle occurs, preventing their uncontrolled proliferation. With respect to pathologically activated myofibroblasts, plasma exposure promotes induction of apoptosis, thereby eliminating cells responsible for excessive collagen synthesis and maintenance of the fibrotic microenvironment.
An important aspect is the selectivity of low-temperature plasma action: physiologically active cells retain their viability, whereas pathologically activated cells undergo functional inactivation or apoptosis. This makes it possible to reduce fibrosis without damaging surrounding tissues.
One of the most significant effects of low-temperature plasma is its influence on the remodeling processes of the dermal extracellular matrix. Plasma exposure promotes normalization of collagen synthesis by regulating the ratio of type I to type III collagen. This reduces excessive accumulation of dense type I collagen and restores a more physiological architecture of the dermal matrix.
In addition, low-temperature plasma activates matrix metalloproteinases (MMPs), which are responsible for the degradation of excessively synthesized collagen fibers, while simultaneously decreasing the expression of their tissue inhibitors (TIMPs). Restoration of the MMP/TIMP balance contributes to structural reorganization of scar tissue and improvement of its mechanical properties.
As a result of plasma exposure, gradual loosening of dense scar tissue occurs, with improvement in its elasticity and integration with the surrounding dermis, which clinically manifests as a reduction in scar severity and improvement in skin texture.
The antimicrobial effect of low-temperature plasma is обусловлен высокой реакционной способностью RONS, which effectively inactivate a broad spectrum of microorganisms, including bacteria and fungi, without the development of resistance. Elimination of microbial contamination reduces the level of chronic inflammation and removes one of the key triggers of pathological scarring.
In addition, plasma exposure promotes improvement of microcirculation and tissue oxygenation. Stimulation of endothelial cells and modulation of vascular tone lead to enhanced local blood flow, reduced tissue hypoxia, and activation of angiogenesis processes. Improved delivery of oxygen and nutrients creates optimal conditions for physiological dermal remodeling.
The combined antimicrobial and antihypoxic effects of low-temperature plasma make it possible to disrupt the pathological cycle of “inflammation — hypoxia — fibrosis,” rendering plasma technologies particularly promising in the treatment of chronic and resistant scar-related skin changes.
Advantages of Plasma Health in Scar Treatment. The application of the Plasma Health gas ionization methodology in the treatment of scar-related skin changes offers a number of fundamental advantages compared with traditional correction methods. First and foremost, plasma technologies provide an impact on the key pathogenetic mechanisms of scarring rather than solely on the external morphological manifestations of the scar. Modulation of the inflammatory response, normalization of fibroblast activity, and restoration of extracellular matrix remodeling processes allow direct influence on the biological basis of scar tissue formation.
An important advantage of Plasma Health is the possibility of selective intervention—either targeting a newly forming scar or a hypertrophic scar—through the choice between thermal and non-thermal skin treatment modes. The Plasma Health technology provides an athermic effect when required, without inducing coagulative necrosis or mechanical skin damage. This significantly reduces the risk of secondary fibrosis, post-inflammatory hyperpigmentation, and the formation of new scar changes, which is particularly important in patients predisposed to pathological scarring.
The absence of systemic side effects represents another significant aspect of ion-plasma therapy. Unlike pharmacological approaches, ion-plasma therapy does not exert systemic effects on the body, does not disrupt hormonal balance, and does not suppress the immune system. This expands its applicability in patients with comorbidities and allows its use as part of combination therapeutic strategies.
Particular attention should be given to the possibility of applying Plasma Health at various stages of scarring. Plasma exposure may be effective both at early stages of wound healing to prevent pathological scarring and in the presence of established scars to promote their remodeling. The versatility of the method and the possibility of individualized parameter selection make low-temperature plasma a flexible tool in the clinical practice of dermatologists and aesthetic medicine specialists.
In conclusion, scar-related skin changes represent a complex multifactorial problem based on disturbances of the inflammatory response, cellular regulation, and extracellular matrix remodeling. The limited effectiveness of traditional correction methods is обусловлена их преимущественным воздействием на следствия патологического процесса without comprehensive influence on its pathogenetic mechanisms.
Ion-plasma therapy and gas ionization technology demonstrate high potential as promising methods for the pathogenetic correction of skin scars. Their multifactorial action—including anti-inflammatory, antimicrobial, and antihypoxic effects, as well as the ability to modulate fibroblast activity and dermal remodeling processes—allows plasma technologies to be considered a novel direction in the treatment of scar-related changes.
The integration of Plasma Health technologies into clinical dermatology and aesthetic medicine opens prospects for the development of safer, more effective, and individualized scar treatment protocols. Further experimental and clinical studies will help to refine optimal plasma exposure parameters and expand indications for its use, which in the future may significantly transform approaches to the correction of scar-related skin changes.

References

Kurganskaya I. G., Kovlen D. V.
Physical Methods of Post-Acne Scar Correction: Scientometric Analysis of Evidence-Based Research // [Scientific Review]. — An analytical review of physical methods for the correction of post-acne scars, including laser technologies and assessment of their clinical effectiveness.

Talibova A. P., Gryazeva N. V.
Combined Laser Therapy and Autologous Plasma with Cellular Components in Patients with Atrophic Post-Acne Scars // [Clinical Study]. — A study investigating the combined use of laser therapy and autologous plasma with cellular components in patients with atrophic post-acne scars.

Vertyeva N. N. et al.
Review of Pathogenetic Mechanisms and Methods for Scar Correction of Cicatrices // [Literature Review]. — An analysis of the pathogenetic mechanisms of scar formation and a comparative characterization of correction methods, including laser, non-ablative, and fractional technologies.

Low Temperature Plasma Jet Treatment Promotes Skin Wound Healing // PubMed. — An experimental study investigating the mechanisms of skin wound healing stimulation under the influence of low-temperature plasma, including activation of PI3K/AKT and AMPK signaling pathways.

Low-Temperature Cold Plasma Promotes Wound Healing by Inhibiting Skin Inflammation // PubMed. — A study demonstrating the anti-inflammatory effects of cold plasma and increased expression of skin healing factors (VEGF, TGF-β, COL-I, etc.).

Laroussi M.
Cold Gas Plasma Sources and the Science behind Their Applications in Biology and Medicine. — IEEE Transactions on Plasma Science. — A fundamental work devoted to the physics of cold plasma, its generation sources, and the biomedical mechanisms of interaction with biological tissues.